Key Research From the 2013 Genitourinary Cancers Symposium to be Featured in February 12 Presscast

Studies to Highlight Advances in Detection, Treatment of Prostate, Renal Cancers

For immediate release
January 7, 2013

Contact

Susie Tappouni
571-483-1355
Susie.Tappouni@asco.org

ALEXANDRIA, Va. – Three key studies from the 2013 Genitourinary Cancers Symposium will be featured in an embargoed presscast for reporters on Tuesday, February 12, 2013, from 12:00-1:30 PM (EST). These important studies will focus on the latest advances being made in the screening and management of several genitourinary cancers. The presscast will be moderated by Bruce J. Roth, MD, a member of the 2013 Genitourinary Cancers Symposium News Planning Team and chair of ASCO’s Cancer Communications Committee.

During the presscast, which will be held via live teleconference and webinar, researchers will present results from the following three studies:

- A study on the odds of developing low-, intermediate-, and high-risk disease in men with AJCC stage T1cN0M0 PSA-detected prostate cancer (Hong Zhang, MD, PhD, University of Rochester Medical Center, Rochester, NY)
- A trial that evaluated outcomes in men with high-risk prostate cancer who were treated with pelvic radiotherapy and 36 or 18 months of androgen blockade (Abdenour Nabid, MD, FRCP(C), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec City)
- A population-based study that examined the uses and outcomes of surveillance versus surgery in management of small renal masses (William C. Huang, MD, NYU School of Medicine, New York, NY)
Genitourinary cancers include those of the prostate, kidney, bladder and testis, as well as less common cancers such as those of the penis, ureters and other urinary organs. In 2012, an estimated 390,000 people in the United States were diagnosed with genitourinary cancers, with an estimated 58,000 deaths. The most common genitourinary cancer is prostate cancer, which according to estimates, was diagnosed in more than 241,000 men in the United States in 2012, and claimed more than 28,000 lives.

This year’s Symposium will take place February 14 - 16 2013, at the Rosen Shingle Creek in Orlando and feature 475 abstracts on the latest research in genitourinary cancers.

Three leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).


About ASCO:

Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.